Brought to you by 
Forma gives Genentech option to buy cancer candidate
21 Jan 2016
Executive Summary
Roche’s Genentech Inc. has received an exclusive global option to acquire a preclinical cancer candidate from Forma Therapeutics Inc. (addressing challenging oncology drug targets). NOTE: according to PharmaProjects, the candidate is a small-molecule nicotinamide phosphoribosyltransferase inhibitor.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com